Siplizumab not checked

ITB-Med LLC · TCD601

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
9 in total · 5 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class”In the company’s words, NCT07508787 on ClinicalTrials.gov
Tested for
Liver Transplantation, Renal Transplant Failure and Rejection
Main trialPhase 2
“The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.”In the company’s words, NCT06019507 on ClinicalTrials.gov
Other names
TCD601

Other drugs for Liver Transplantation

All 3 drugs for Liver Transplantation

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Jun 2026 A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
Phase 2Recruiting 28 Mar 2028 A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant
Phase 2Completed 3 Oct 2023 A Dose Escalation Study in de Novo Renal Transplantation
Phase 2Terminated 11 Dec 2024 A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
Phase 2Terminated 24 Jul 2025 A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
Phase 2Terminated 30 Oct 2025 A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
Phase 2Terminated 17 Feb 2026 A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
Phase 2Completed 10 Apr 2026 A Study of TCD601 in de Novo Renal Transplant Recipients
Phase 1Terminated 2 Jul 2026 A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Siplizumab

Following is part of Solo: you see every change to Siplizumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in